Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

William Mitchell

Family Medicine Morgantown, WV Medical Doctor

NPI 1568433571 CMS profile 343685

6000 Memorial Church Drive, Morgantown, WV 26501

Open in the dashboard

General payments

$15,849

1,046 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, William Mitchell of Morgantown, WV is reported in the CMS Open Payments database as having received $15,849 across 1,046 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,390 123
2024 General $2,863 174
2023 General $2,368 146
2022 General $2,424 166
2021 General $1,250 76
2020 General $1,328 88
2019 General $3,226 273

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Mitchell
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to William Mitchell were reported at $2,390. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year William Mitchell Family Medicine median Middle half National median
2019 $3,226 $150 $41–$543 $163
2020 $1,328 $120 $32–$415 $114
2021 $1,250 $137 $35–$551 $132
2022 $2,424 $137 $37–$512 $149
2023 $2,368 $149 $42–$545 $160
2024 $2,863 $156 $44–$560 $164
2025 $2,390 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,290 168 payments
  2. Novo Nordisk Inc $2,019 124 payments
  3. AstraZeneca Pharmaceuticals LP $1,795 66 payments
  4. Pfizer Inc. $1,165 95 payments
  5. Lilly USA, LLC $946 63 payments
  6. GlaxoSmithKline, LLC. $595 51 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $560 35 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $513 32 payments
  9. Amgen Inc. $507 47 payments
  10. Astellas Pharma US Inc $488 29 payments
  11. Other $4,970 336 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $15,811 1,043 payments
  2. Education $38 3 payments
Products named General payments · program years 2019–2025
  1. Ozempic $1,465 90 payments
  2. RYBELSUS $1,023 52 payments
  3. FARXIGA $997 29 payments
  4. UBRELVY $969 47 payments
  5. AIRSUPRA $609 17 payments
  6. BEVESPI AEROSPHERE $583 8 payments
  7. QULIPTA $567 24 payments
  8. LINZESS $547 66 payments
  9. XIFAXAN $527 33 payments
  10. ELIQUIS $522 41 payments
  11. Other $15,284 1,081 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 165 drugs

Part D claims

14,280

Median for Family Practice: 1,826

Drug cost

$1,736,953

Median for Family Practice: $120,094

Branded share of claims

21.7%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 354 $407,739
Mounjaro Tirzepatide Brand 223 $287,388
Trulicity Dulaglutide Brand 113 $172,340
Jardiance Empagliflozin Brand 93 $136,557
Ozempic Semaglutide Brand 107 $118,386
Xarelto Rivaroxaban Brand 45 $45,099
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 26 $40,957
Tresiba Flextouch U-200 Insulin Degludec Brand 45 $34,108
Entresto Sacubitril/Valsartan Brand 27 $32,125
Tresiba Flextouch U-100 Insulin Degludec Brand 38 $31,687

The 10 drugs with the highest cost, of 165 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Records

1,046 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record